Mostrar el registro sencillo

dc.contributor.authorBrown, Emmeline E.
dc.contributor.authorBlauwendraat, Cornelis
dc.contributor.authorTrinh, Joanne
dc.contributor.authorRizig, Mie
dc.contributor.authorNalls, Mike A.
dc.contributor.authorLeveille, Etienne
dc.contributor.authorRuskey, Jennifer A.
dc.contributor.authorJonvik, Hallgeir
dc.contributor.authorTan, Manuela M.X.
dc.contributor.authorBandres-Ciga, Sara
dc.contributor.authorHassin-Baer, Sharon
dc.contributor.authorBrockmann, Kathrin
dc.contributor.authorInfante Ceberio, Jon 
dc.contributor.authorTolosa, Eduardo
dc.contributor.authorEzquerra, Mario
dc.contributor.authorRomdhan, Sawssan Ben
dc.contributor.authorBenmahdjoub, Mustapha
dc.contributor.authorArezki, Mohamed
dc.contributor.authorMhiri, Chokri
dc.contributor.authorHardy, John
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-02-22T19:06:32Z
dc.date.available2022-02-22T19:06:32Z
dc.date.issued2021-01
dc.identifier.issn0197-4580
dc.identifier.issn1558-1497
dc.identifier.urihttp://hdl.handle.net/10902/24020
dc.description.abstractThe LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson?s disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n ¼ 724) and meta-analyzed our data with previously published data (n ¼ 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common vari- ation in LRRK2 and VAMP4 in disease riskes_ES
dc.format.extent8 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© <2021>. This manuscript version is made available under the CC-BY-NC-ND 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceNeurobiology of Aging, Volume 97, January 2021, Pages 148.e17-148.e24es_ES
dc.subject.otherParkinson’s diseasees_ES
dc.subject.otherGenetic modifierses_ES
dc.subject.otherParkinsonismes_ES
dc.subject.otherLeucine-rich repeat kinase 2es_ES
dc.titleAnalysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson´s diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.neurobiolaging.2020.07.002es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1016/j.neurobiolaging.2020.07.002
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© <2021>. This manuscript version is made available under the CC-BY-NC-ND 4.0 licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © <2021>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license